淋巴细胞表型在系统性自身免疫病精准医学中的应用
本文综述了通过免疫表型分析对系统性红斑狼疮(SLE)患者进行T细胞异质性亚组划分的研究,发现活动性SLE可分为3个亚组,且滤泡辅助性T细胞主导组治疗耐药最常见。结合银屑病关节炎(PsA)中基于外周辅助性T细胞表型差异选择不同生物制剂的策略,提出对高异质性疾病进行亚组划分可为精准医学奠定基础。
要点
- 活动性SLE患者基于T细胞异质性可分为3个亚组。
- 滤泡辅助性T细胞主导组中治疗耐药患者最常见。
- PsA中基于外周辅助性T细胞表型差异策略性选择生物制剂或可实现精准医学。
核心结论
- 对SLE等高异质性疾病进行免疫表型亚组划分可为精准医学提供基础,并推动治疗策略制定。
研究设计与样本
- 本文为综述,基于免疫表型分析对SLE患者进行T细胞异质性亚组划分,并扩展至PsA中生物制剂选择的精准医学概念。
主要发现
- 活动性SLE患者基于T细胞异质性可分为3个亚组。
- 即使临床特征相似的患者间免疫表型特征也不同。
- 治疗耐药患者最常出现在滤泡辅助性T细胞主导组。
- PsA中基于个体患者外周辅助性T细胞表型差异策略性选择不同生物制剂具有精准医学潜力。
关键数值与推荐
- 活动性SLE基于T细胞异质性分为3个亚组。
- 治疗耐药患者最常出现在滤泡辅助性T细胞主导组。
临床怎么用
- 对SLE等高临床与分子异质性疾病,可考虑通过免疫表型亚组划分指导治疗策略。
- 在PsA中可根据个体患者外周辅助性T细胞表型差异策略性选择不同生物制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic lupus erythematosus (SLE) is a representative autoimmune disease characterized by multiple organ manifestations but is molecularly and genetically heterogeneous which makes difficult to manage every case based on one kinetic molecular theory. We, therefore, have tried to obtain a broader perspective on the molecular heterogeneity in SLE by immunophenotyping and found that patients with active SLE can be divided into 3 subgroups based on T cell heterogeneity. Although immunophenotypic features were different even among patients with similar clinical features, patients resistant to treatment were most frequently seen in the follicular helper T cell-dominant group. Because belimumab is only approved targeted therapy for SLE, the concept was encompassed with psoriatic arthritis (PsA) for which multiple biologics are approved. The obtained results suggest the potential for precision medicine via the strategic selection of different biologics based on the phenotypic differences in peripheral helper T cells in individual patients with PsA. Thus, subgrouping heterogeneous diseases could provide good bases for precision medicine, which would encourage treatment strategies of diseases with high clinical and molecular heterogeneity such as SLE.
引用
- Tanaka Y, Kubo S, Miyagawa I, et al. Lymphocyte phenotype and its application to precision medicine in systemic autoimmune diseases✰. Semin Arthritis Rheum. 2019. PMID: 31079846. doi:10.1016/j.semarthrit.2019.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。